These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 7494376)
1. Loxiglumide, L-364,718 and L-365,260 prevent the inhibition of spontaneous acetylcholine release from the frontal cerebral cortex of freely moving rat peripherally administered with cholecystokinin-8S. Kimura I; Wakasono S; Kimura M Jpn J Pharmacol; 1995 May; 68(1):129-32. PubMed ID: 7494376 [TBL] [Abstract][Full Text] [Related]
2. Preferential blockade of cholecystokinin-8S-induced increases in aspartate and glutamate levels by the CCK(B) receptor antagonist, L-365,260, in rat brain. Ge J; Long SK; Kilpatrick IC Eur J Pharmacol; 1998 Mar; 345(2):163-70. PubMed ID: 9600632 [TBL] [Abstract][Full Text] [Related]
3. Effect of cholecystokinin on acetylcholine turnover and dopamine release in the rat striatum and cortex. Cosi C; Altar AC; Wood PL Eur J Pharmacol; 1989 Jun; 165(2-3):209-14. PubMed ID: 2776829 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini. Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413 [TBL] [Abstract][Full Text] [Related]
5. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice. Hirosue Y; Inui A; Miura M; Nakajima M; Okita M; Himori N; Baba S; Kasuga M Peptides; 1992; 13(1):155-7. PubMed ID: 1620653 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754 [TBL] [Abstract][Full Text] [Related]
8. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. O'Neill MF; Dourish CT; Iversen SD Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197 [TBL] [Abstract][Full Text] [Related]
9. Elevation of feed intake in parasite-infected lambs by central administration of a cholecystokinin receptor antagonist. Dynes RA; Poppi DP; Barrell GK; Sykes AR Br J Nutr; 1998 Jan; 79(1):47-54. PubMed ID: 9505802 [TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry. Reum T; Schäfer U; Marsden CA; Fink H; Morgenstern R Neuropeptides; 1997 Feb; 31(1):82-8. PubMed ID: 9574843 [TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes. You ZB; Godukhin O; Goiny M; Nylander I; Ungerstedt U; Terenius L; Hökfelt T; Herrera-Marschitz M Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):576-81. PubMed ID: 9151295 [TBL] [Abstract][Full Text] [Related]
12. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021 [TBL] [Abstract][Full Text] [Related]
13. A cholecystokinin receptor antagonist, loxiglumide, stimulates biliary secretion in conscious rats. Watanabe N; Otsuki M Eur J Pharmacol; 1994 Nov; 264(3):331-6. PubMed ID: 7698173 [TBL] [Abstract][Full Text] [Related]
14. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas. Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557 [TBL] [Abstract][Full Text] [Related]
15. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin. Altar CA; Boyar WC Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523 [TBL] [Abstract][Full Text] [Related]
16. Type-A CCK receptors mediate the inhibition of food intake and activity by CCK-8 in 9- to 12-day-old rat pups. Smith GP; Tyrka A; Gibbs J Pharmacol Biochem Behav; 1991 Jan; 38(1):207-10. PubMed ID: 2017446 [TBL] [Abstract][Full Text] [Related]
17. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Crawley JN J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584 [TBL] [Abstract][Full Text] [Related]
18. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells. Staley J; Jensen RT; Moody TW Peptides; 1990; 11(5):1033-6. PubMed ID: 2178246 [TBL] [Abstract][Full Text] [Related]
19. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide. Boyle SJ; Tang KW; Woodruff GN; McKnight AT Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944 [TBL] [Abstract][Full Text] [Related]
20. Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose ganglia. Widdop RE; Krstew E; Mercer LD; Carlberg M; Beart PM; Jarrott B J Auton Nerv Syst; 1994; 46(1-2):65-73. PubMed ID: 8120343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]